All Title Author
Keywords Abstract


The Impact of miRNA-155 Expression on Treatment Outcome in Adult Acute Myeloid Leukemia Patients

DOI: 10.4236/jct.2019.103017, PP. 203-214

Keywords: miR-155, Micro-RNA, AML

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Acute myeloid leukemia is a heterogeneous hematologic malignancy associated with gene mutations, chromosomal rearrangements, deregulation of gene expression and epigenetic modifications. The treatment outcome of AML is highly variable signifying the heterogeneous nature of the disease. Aim of the Study: To evaluate miRNA-155 expression level as a prognostic marker for adult patients with acute myeloid leukemia. Patients and Methods: 101 subjects were included in this study. They were classified into 2 groups, patient group (61 adult patients with newly diagnosed acute myeloid leukemia) and control group (40 apparently healthy adult subjects). miRNA-155 expression was assessed using real time PCR using QIAGEN, miScript, Quanti Tect and Rotor-isc (QIAGEN Group) PAXgene (pre Analytix Gmbh). Samples were either peripheral blood or bone marrow aspiration sample. Results: Roc curve detected 2.85 as best fit value of miRNA-155 for discriminating patients from healthy controls with sensitivity 92.3%, specificity 88.5%, AUC 0.98 and CI (0.96 - 0.99) (p < 0.001). The 75th percentile value of the patient group was taken as prognostic cut off value with a value < 9.8 as low miRNA-155 and a value ≥ 9.8 as high miRNA-155. The expression level of miRNA-155 was significantly higher in AML patients than in controls (p = 0.002). Patients with high miRNA expression had a significantly higher white blood cells count (p = 0.002), bone marrow blasts (p = 0.006) and peripheral blood blasts (p = 0.006) compared to patients with low miRNA-155 expression. Patients with poor cytogentics had a significantly higher level of miRNA-155 expression compared to patients with favorable cytogentics (p = 0.007). The complete remission rate was significantly higher in patients with low miRNA-155 expression compared to those with high expression

References

[1]  Bartel, D.P. (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell, 116, 281-297.
https://doi.org/10.1016/S0092-8674(04)00045-5
[2]  Tili, E., Michaille, J.J., Wernicke, D., et al. (2011) Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer. Proceedings of the National Academy of Sciences of the United States of America, 108, 4908-4913.
https://doi.org/10.1073/pnas.1101795108
[3]  Tili, E., Croce, C.M. and Michaille, J.J. (2009) miR-155: On the Crosstalk between Inflammation and Cancer. International Reviews of Immunology, 28, 264-284.
https://doi.org/10.1080/08830180903093796
[4]  Costinean, S., Sandhu, S.K., Pedersen, I.M., et al. (2009) Src Homology 2 Domain-Containing Inositol-5-Phosphatase and CCAAT Enhancer-Binding Protein β Are Targeted by miR-155 in B Cells of Eμ-MiR-155 Transgenic Mice. Blood, 114, 1374-1382.
https://doi.org/10.1182/blood-2009-05-220814
[5]  Gerloff, D., Grundler, R., Wurm, A.A., et al. (2015) NF-κB/STAT5/miR-155 Network Targets PU.1 in FLT3-ITD-Driven Acute Myeloid Leukemia. Leukemia, 29, 535-547.
https://doi.org/10.1038/leu.2014.231
[6]  Marcucci, G., Maharry, K.S., Metzeler, K.H., et al. (2013) Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. Journal of Clinical Oncology, 31, 2086-2093.
https://doi.org/10.1200/JCO.2012.45.6228
[7]  Obad, S., dos Santos, C.O., Petri, A., et al. (2011) Silencing of microRNA Families by Seed-Targeting Tiny LNAs. Nature Genetics, 43, 371-378.
https://doi.org/10.1038/ng.786
[8]  Van Roosbroeck, K., Fanini, F., Setoyama, T., Ivan, C., Rodriguez-Aguayo, C., Fuentes-Mattei, E., et al. (2017) Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 23, 2891-2904.
https://doi.org/10.1158/1078-0432.CCR-16-1025
[9]  Ranganath, P. (2015) MicroRNA-155 and Its Role in Malignant Hematopoiesis. Biomarker Insights, 10, 95-102.
https://doi.org/10.4137/BMI.S27676
[10]  Tang, L., Peng, Y.-Z., Li, C.-G., Jiang, H.-W., Mei, H. and Hu, Y. (2019) Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-Analysis. Journal of Cancer, 10, 654-664.
https://doi.org/10.7150/jca.28537
[11]  Babar, I.A., Cheng, C.J., Booth, C.J., Liang, X., Weidhaas, J.B., Saltzman, W.M. and Slack, F.J. (2012) Nanoparticle-Based Therapy in an in Vivo microRNA-155 (miR-155)-Dependent Mouse Model of Lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 109, E1695-E1704.
https://doi.org/10.1073/pnas.1201516109
[12]  Livak, K.J. and Schmittgen, T.D. (2001) Analysis of Relative Gene Expression Data Using Real Time Quantitive PCR and the 2-△△CT Method. Methods, 25, 402-408.
https://doi.org/10.1006/meth.2001.1262
[13]  Estey, E.H. (2014) Acute Myeloid Leukemia: 2014 Update on Risk Stratification and Management. American Journal of Hematology, 89, 1064-1081.
https://doi.org/10.1002/ajh.23834
[14]  Elton, T.S., Selemon, H., Elton, S.M., et al. (2013) Regulation of the MIR155 Host Gene in Physiological and Pathological Processes. Gene, 532, 1-12.
https://doi.org/10.1016/j.gene.2012.12.009
[15]  Ramamurthy, R., Hughes, M., Morris, V., Bolouri, H., et al. (2016): miR-155 Expression and Correlation with Clinical Outcome in Pediatric AML: A Report from Children’s Oncology Group. Pediatric Blood & Cancer, 63, 2096-2103.
[16]  Zhi, F., Cao, X., Xie, X., Wang, B., Dong, W., Gu, W., et al. (2013) Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Myeloid Leukemia. PLoS ONE, 8, e56718.
https://doi.org/10.1371/journal.pone.0056718
[17]  Xu, L.-H., Guo, Y., Cen, J.N., Yan, W.-Y., He, H.L., et al. (2015) Overexpressed miR-155 Is Associated with Initial Presentation and Poor Outcome in Chinese Pediatric Acute Myeloid Leukemia. European Review for Medical and Pharmacological Sciences, 19, 4841-4850.
[18]  O’Connell, R.M., Rao, D.S., Chaudhuri, A.A., et al. (2008) Sustained Expression of MicroRNA-155 in Hematopoietic Stem Cells Causes a Myeloproliferative Disorder. The Journal of Experimental Medicine, 205, 585-594.
https://doi.org/10.1084/jem.20072108
[19]  Hu, X.L. and Tang, A.P. (2016) Expression of miR-155 in Acute Myeloid Leukemia and Its Clinical Significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 24, 980-984.
[20]  Chuang, M.K., Chiu, Y.-C., Chou, W.-C., Hou, H.-A., Chuang, E.Y. and Tien, H.-F. (2015) A 3-MicroRNA Scoring System for Prognostication in de Novo Acute Myeloid Leukemia Patients. Leukemia, 29, 1051-1059.
https://doi.org/10.1038/leu.2014.333
[21]  Croce, C.M. (2013) MicroRNA Dysregulation in Acute Myeloid Leukemia. Journal of Clinical Oncology, 31, 2065-2066.
https://doi.org/10.1200/JCO.2013.48.8239

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal